// App-Quantinova.ai

2731 : A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

Researchers

Presenter

  • Scott E. Smith

Principal Investigators

  • Joyce Steinberg

  • Renelle Papa

  • Javier Lopez-Jimenez

  • Anne Keating

  • Antoine Thyss

Medical Centers

  • Hematologie-Oncologie Medicale, Nice Cedex , France

  • Servicio Hematologia y Hemoterapia, Hospital Universitario Ramon y Cajal, Madrid, Spain

Locations

  • France

  • Spain

Companies

  • South Texas Accelera

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Diffuse large B-cell lymphoma

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Thrombocytopenia

  • Non‐Hodgkin Lymphoma

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

  • Postaxial polydactyly

Biomarkers

  • N/A

Drug/Treatment

  • sepantronium bromide

  • Rituximab

  • YM155

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved